Finding the right dose of fulvestrant in breast cancer.

L Estévez, I Alvarez, I Tusquets, M A Seguí, M Muñoz, Y Fernández, A Lluch

Medical Oncology Department, Centro Integral Oncológico Clara Campal, Madrid, Spain. lauraestevez@hospitaldemadrid.com

Cancer treatment reviews 2013 Apr

filter terms:

Fulvestrant is a selective estrogen receptor downregulator, behaving as a complete antagonist. It was initially approved, at a dose of 250 mg, to treat hormone dependant breast cancer in second line setting. However, a series of pharmacological and pre-clinical studies have suggested that a higher dose of 500 mg may be more effective. The present work summarizes and discusses clinical trials that have aimed to test the benefits of administering fulvestrant at a higher dose. The data support the use of a higher, and more possibly, effective dose of the agent. Copyright © 2012 Elsevier Ltd. All rights reserved.

Citation

L Estévez, I Alvarez, I Tusquets, M A Seguí, M Muñoz, Y Fernández, A Lluch. Finding the right dose of fulvestrant in breast cancer. Cancer treatment reviews. 2013 Apr;39(2):136-41